Sight Sciences Inc (SGHT) - Net Assets
Based on the latest financial reports, Sight Sciences Inc (SGHT) has net assets worth $64.29 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($116.26 Million) and total liabilities ($51.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Sight Sciences Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.29 Million |
| % of Total Assets | 55.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.53 |
Sight Sciences Inc - Net Assets Trend (2018–2024)
This chart illustrates how Sight Sciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Sight Sciences Inc (SGHT) total assets for the complete picture of this company's asset base.
Annual Net Assets for Sight Sciences Inc (2018–2024)
The table below shows the annual net assets of Sight Sciences Inc from 2018 to 2024. For live valuation and market cap data, see Sight Sciences Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $87.52 Million | -27.19% |
| 2023-12-31 | $120.22 Million | -24.90% |
| 2022-12-31 | $160.08 Million | -31.03% |
| 2021-12-31 | $232.11 Million | +361.24% |
| 2020-12-31 | $-88.85 Million | -62.48% |
| 2019-12-31 | $-54.68 Million | -88.81% |
| 2018-12-31 | $-28.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sight Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31681800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $51.00K | 0.06% |
| Other Components | $433.77 Million | 495.61% |
| Total Equity | $87.52 Million | 100.00% |
Sight Sciences Inc Competitors by Market Cap
The table below lists competitors of Sight Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VIETNAM HOLDING LTD
F:2YL
|
$235.30 Million |
|
American Realty Investors Inc
NYSE:ARL
|
$235.34 Million |
|
Funko Inc
NASDAQ:FNKO
|
$235.39 Million |
|
BAJEL PROJECTS LTD
NSE:BAJEL
|
$235.61 Million |
|
Ernst Russ AG
XETRA:HXCK
|
$235.15 Million |
|
Lewis Group Limited
JSE:LEW
|
$235.10 Million |
|
Adimmune Corp
TW:4142
|
$235.05 Million |
|
Otovo AS
OL:OTOVO
|
$235.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sight Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 120,215,000 to 87,523,000, a change of -32,692,000 (-27.2%).
- Net loss of 51,507,000 reduced equity.
- Other factors increased equity by 18,815,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.51 Million | -58.85% |
| Other Changes | $18.82 Million | +21.5% |
| Total Change | $- | -27.19% |
Book Value vs Market Value Analysis
This analysis compares Sight Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.90 | $4.45 | x |
| 2019-12-31 | $-1.63 | $4.45 | x |
| 2020-12-31 | $-1.90 | $4.45 | x |
| 2021-12-31 | $4.89 | $4.45 | x |
| 2022-12-31 | $3.35 | $4.45 | x |
| 2023-12-31 | $2.47 | $4.45 | x |
| 2024-12-31 | $1.75 | $4.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sight Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -64.49%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.63x
- Recent ROE (-58.85%) is below the historical average (-26.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -189.77% | 0.93x | 0.00x | $-11.39 Million |
| 2019 | 0.00% | -110.80% | 0.76x | 0.00x | $-20.40 Million |
| 2020 | 0.00% | -125.52% | 0.38x | 0.00x | $-25.81 Million |
| 2021 | -27.13% | -128.61% | 0.17x | 1.21x | $-86.17 Million |
| 2022 | -53.88% | -120.90% | 0.33x | 1.33x | $-102.25 Million |
| 2023 | -46.21% | -68.53% | 0.49x | 1.39x | $-67.57 Million |
| 2024 | -58.85% | -64.49% | 0.56x | 1.63x | $-60.26 Million |
Industry Comparison
This section compares Sight Sciences Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sight Sciences Inc (SGHT) | $64.29 Million | 0.00% | 0.81x | $235.28 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeo… Read more